InnovaDerma PLC
("InnovaDerma" or the "Company")
Interim Results for the 6 months ended 31 December 2021
InnovaDerma (LSE: IDP), a leading digitally focused
Financial Highlights
|
H1 2022 |
H1 20211 |
Change |
|
|
|
|
Revenue2 |
|
|
(9.5%) |
Gross profit |
|
|
3.1% |
Gross margin |
56.3% |
49.4% |
690 bps |
Adjusted EBITDA3 |
( |
( |
|
Basic EPS |
( |
( |
|
Cash and cash equivalents |
|
|
|
1 See note 2.3 for a description of the prior year restatement.
2 On a constant currency basis
3 Adjusted EBITDA defined as EBITDA before non-recurring items, including impairments, abortive and restructuring costs. A reconciliation of adjusted EBITDA can be found in note 5 below.
Operational Highlights
Our strategy of driving increased profitable sales through gross margin improvement, radical simplification of business operations, rigorous cost control and the prioritisation of our Skinny Tan brand, is working.
Financial performance is markedly improved vs H1 2020. Our previously announced strategy has been implemented with a disciplined approach to marketing and overhead costs.
Short-term impact on revenue (revenues of c.
Adjusted EBITDA improved significantly to
We have further improved our return on marketing spend to 38.1% (H1 21: 40.0%, H2 21: 39.2%) and have reduced less-efficient marketing spend during the low tanning season to ensure we have the right ammunition to maximise returns over the peak H2 tanning season (
Our Liberty Poole collaboration continues to yield benefits and is helping to increase the share of our business in the key 18-25 age group.
Global Amazon relationship already delivering material sales in lead
Enhanced e-commerce operational excellence with 76% of customers giving Skinnytan.co.uk 5 stars.
Joint venture agreement signed in December 2021 to accelerate sales of the Prolong medical device, with InnovaDerma plc retaining 45% stake in the business, and enabling the Group to focus on its topical products.
Outlook
The Board remains optimistic that the transformation plan enacted this year, as well as underlying improved consumer consumption and retail momentum versus last year will enable the business to continue its improvement trajectory over the second half year with a return to profitability this year remaining the Board's intention. The second half of our financial year has historically been considerably stronger than the first, driven by Skinny Tan in the
Blake Hughes, CEO InnovaDerma plc, commented:
"We continue to make good progress in simplifying and reshaping our business as we focus on delivering sustainable, profitable revenue growth. It is pleasing to see that our strategy is delivering tangible financial improvements.
"We have a strong foundation for the second half of the year, especially as the focus on Amazon and our Liberty Poole collaboration are delivering strong benefits, even before peak tanning season. This will be supported by our well-honed digital capabilities and conversion optimised e-commerce site and exciting new Skinny Tan product launches which have already received excellent retailer support."
Further enquiries
InnovaDerma Blake Hughes |
c/o TB Cardew |
finncap Ltd Geoff Nash/Kate Bannatyne Alice Lane - Corporate Broking |
+44 (0)207 220 0500 |
TB Cardew |
|
Shan Shan Willenbrock/ |
+ 44 (0)7775 848537 |
Olivia Rosser |
+ 44 (0)7552 864250 |
|
Non-Executive Chairman's statement
I am pleased to deliver the Company's interim results for the period ended 31 December 2021.
The Company's change in strategy, to concentrate on driving increased profitable sales, ceasing loss making promotions and prioritising Skinny Tan, has been endorsed by the improvement in the Company's operating performance for the six months to 31 December 2021, as outlined in the Trading Update issued on 12 January 2022 and in the interim results announced today.
I am pleased to be able to report an improvement in gross margin, EBITDA and EPS.
Strategic report: Chief Executive's report
As previously detailed in our annual results published in December, the Group has implemented a number of necessary operational and financial interventions to transform and future-proof the business. The action plan focused on:
1. Optimising our organisation
Our business is only as strong as our people and how they collaborate as a team. The focus remains to ensure that we have the right people, in the right country, with the right skills, focused on the right targets and powered by the right mindset.
2. Strengthen our financial foundations
During H1 21 we have significantly reduced the EBITDA loss versus the prior year, with a laser-like focus on improving gross margins, reducing non-productive inventory, cutting low return costs and introducing real time accurate financial profitability metrics.
3. Focusing our resources on our priority brands
Skinny Tan is our flagship brand and number one priority. Despite its ongoing success there remain significant profitable growth opportunities when compared to successful global beauty brands. Given the effects of the pandemic we have further strengthened our e-commerce foundations in the
4. Improve our customer experience online and in store
Our enhanced brand architecture and new packaging is rolling out on priority brands Skinny Tan and Charles + Lee, and we expect both to enhance the consumers' online and instore shopping experience. Initial consumer and retailer reaction to the new packaging, as well as our new product innovations for 2023, has been extremely positive..
5. Modernising our customer acquisition marketing model
We now have in place a modern, nuanced digital marketing strategy that leverages the full gamut of digital media. As well as our expertise in social media advertising, the model now includes a strong focus on cost-effective e-mail marketing and high-return influencer marketing, all supported by a conversion optimised e-commerce site.
Our performance
Our strategy of driving increased profitable sales through gross margin improvement, radical simplification of business operations, rigorous cost control and the prioritisation of our Skinny Tan brand, is working.
Skinny Tan is the Company's largest brand (84% of revenue) and highest priority future growth driver. The previously communicated strategic decision to move away from certain loss leading sales led to a reduction in sales but is consistent with the Group's strategic focus on longer-term profitability. Amazon is now the Company's 3rd largest retailer, with further significant future growth anticipated as we enter the peak tanning season. This sales channel is becoming increasingly significant whilst allowing us to achieve a healthy margin.
Charles + Lee has shown excellent retail sales growth though revenues of c.
Investment in Roots and Nuthing has been deprioritised as we focus on Skinny Tan and Charles + Lee as the Company's priority growth brands.
As previously announced, the Company entered into a Joint Venture for the Prolong brand in Dec 2021. Prolong revenues prior to the partnership agreement are included in our consolidated figures. Revenues after the partnership agreement are excluded from our consolidated figures and from future forecasts, however, InnovaDerma will directly benefit from any future dividends which are paid by the Joint Venture and/or any proceeds achieved by a future sale of the business.
Financial review
The Group has reported an increased gross profit of
Marketing efficiency continues to improve, to 38.1% (H1 21: 40.0%, H2 21: 39.2%), as the Group diversifies its digital strategy, including a strong focus on cost effective e-mail marketing and a conversion optimised e-commerce site, that goes beyond a pure Facebook play.
Adjusted EBITDA improved to
Cash
Cash reaches a seasonal low at the half year as we invest in appropriate levels of inventory ahead of the peak Skinny Tan
Previous ad hoc funding, including seasonal invoice factoring, deferred VAT (COVID-19), and HMRC repayment plans, have been replaced by a single CBILS loan of
Dividends
The Board has elected not to declare an interim dividend.
Directors' report: Directors' responsibility statement
The Directors confirm that this condensed, consolidated interim financial information has been prepared in accordance with International Accounting Standard 34, 'Interim Financial Reporting', as adopted by the European Union, and that the half year management report herein includes a fair review of the information required by DTR 4.2.7 and DTR 4.2.8, namely:
· An indication of important events that have occurred during the first six months and their impact on the condensed, consolidated interim financial information, and a description of the principal risks and uncertainties for the remaining six months of the financial year; and
· Material related party transactions in the first six months and any material changes in the related party transactions described in the last annal report.
Unaudited consolidated statement of comprehensive income
For the six months ended 31 December 2021
|
|
Unaudited 6 months ended 31 December 2021 £'000 |
|
Unaudited 6 months ended 31 December 2020 (restated1) £'000 |
|
Audited year ended 30 June 2021 £'000 |
|
|
|
|
|
|
|
Continuing operations |
|
|
|
|
|
|
Revenue |
|
3,689 |
|
4,077 |
|
10,211 |
Cost of sales |
|
(1,613) |
|
(2,064) |
|
(4,421) |
|
|
|
|
|
|
|
Gross profit |
|
2,076 |
|
2,013 |
|
5,790 |
|
|
|
|
|
|
|
Marketing expenses |
|
(1,405) |
|
(1,632) |
|
(4,036) |
Wages and salaries expenses |
|
(813) |
|
(837) |
|
(1,731) |
Administrative expenses |
|
(810) |
|
(958) |
|
(1,902) |
|
|
|
|
|
|
- |
|
|
|
|
|
|
|
Loss from operations |
|
(952) |
|
(1,414) |
|
(1,879) |
|
|
|
|
|
|
|
Finance credit / (cost) |
|
2 |
|
- |
|
(4) |
|
|
|
|
|
|
|
Operating loss before tax |
|
(950) |
|
(1,414) |
|
(1,883) |
|
|
|
|
|
|
|
Taxation credit / (charge) |
|
2 |
|
- |
|
(371) |
|
|
|
|
|
|
|
Operating loss after tax |
|
(948) |
|
(1,414) |
|
(2,254) |
|
|
|
|
|
|
|
Other comprehensive Income |
|
|
|
|
|
|
Exchange income on foreign currency net investments |
|
(6) |
|
(16) |
|
20 |
|
|
|
|
|
|
|
Total comprehensive expense for the period |
|
(954) |
|
(1,430) |
|
(2,234) |
|
|
|
|
|
|
|
Attributable to: |
|
|
|
|
|
|
Owners of the parent |
|
(942) |
|
(1,394) |
|
(2,246) |
Non-controlling interests |
|
(12) |
|
(36) |
|
12 |
|
|
|
|
|
|
|
Loss per share |
|
|
|
|
|
|
Basic and diluted (£) |
|
(0.03) |
|
(0.10) |
|
(0.13) |
1 See note 2.3 for a description of the prior year restatement.
Unaudited consolidated Statement of Financial Position
As at 31 December 2021
|
|
£'000 |
Unaudited 31 December 2021 £'000 |
|
£'000 |
Unaudited 31 December 2020 (restated1) £'000 |
|
£'000 |
Audited 30 June 2021
£'000 |
Non-current assets |
|
|
|
|
|
|
|
|
|
Goodwill |
|
|
214 |
|
|
439 |
|
|
439 |
Investments in associates |
|
|
225 |
|
|
- |
|
|
- |
Other intangible assets |
|
|
193 |
|
|
115 |
|
|
230 |
Property, plant and equipment |
|
|
194 |
|
|
225 |
|
|
233 |
Deferred tax asset |
|
|
- |
|
|
382 |
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
826 |
|
|
1,161 |
|
|
902 |
|
|
|
|
|
|
|
|
|
|
Current assets |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
1,333 |
|
|
151 |
|
|
2,338 |
|
Inventories |
|
2,323 |
|
|
2,411 |
|
|
1,808 |
|
Trade and other receivables |
|
1,369 |
|
|
991 |
|
|
1,896 |
|
|
|
|
|
|
|
|
|
|
|
|
|
5,025 |
|
|
3,553 |
|
|
6,042 |
|
|
|
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
|
|
Trade and other payables |
|
(2,467) |
|
|
(4,480) |
|
|
(3,547) |
|
Borrowings |
|
(144) |
|
|
- |
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
(2,611) |
|
|
(4,480) |
|
|
(3,547) |
|
|
|
|
|
|
|
|
|
|
|
Net current assets |
|
|
2,414 |
|
|
(927) |
|
|
2,495 |
|
|
|
|
|
|
|
|
|
|
Total assets less current liabilities |
|
|
3,240 |
|
|
234 |
|
|
3,397 |
|
|
|
|
|
|
|
|
|
|
Non-current liabilities |
|
|
|
|
|
|
|
|
|
Borrowings |
|
(1,064) |
|
|
- |
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1,064) |
|
|
- |
|
|
- |
|
|
|
|
|
|
|
|
|
|
Net assets |
|
|
2,176 |
|
|
234 |
|
|
3,397 |
|
|
|
|
|
|
|
|
|
|
Equity |
|
|
|
|
|
|
|
|
|
Share capital |
|
|
2,916 |
|
|
1,738 |
|
|
2,859 |
Share premium account |
|
|
11,380 |
|
|
8,288 |
|
|
11,193 |
Merger reserve |
|
|
(721) |
|
|
(721) |
|
|
(721) |
Foreign exchange reserve |
|
|
276 |
|
|
246 |
|
|
282 |
Share-based payment reserve |
|
|
16 |
|
|
10 |
|
|
10 |
Accumulated losses |
|
|
(11,691) |
|
|
(9,319) |
|
|
(10,262) |
|
|
|
|
|
|
|
|
|
|
Equity attributable to owners of parent |
|
|
2,176 |
|
|
242 |
|
|
3,361 |
|
|
|
|
|
|
|
|
|
|
Non-controlling interest |
|
|
- |
|
|
(8) |
|
|
36 |
|
|
|
|
|
|
|
|
|
|
Total equity |
|
|
2,176 |
|
|
234 |
|
|
3,397 |
1 See note 2.3 for a description of the prior year restatement.
Unaudited consolidated Statement of Changes in Equity
For the six months ended 31 December 2021
|
Share capital £'000 |
Share premium £'000 |
Merger reserve £'000 |
Foreign exchange reserve £'000 |
Share-based payment reserve £'000 |
Accumulated losses attributable to owners of parent £'000 |
Equity attributable to owners of parent £'000 |
Non-controlling interests £'000 |
Total equity £'000 |
|
|
|
|
|
|
|
|
|
|
Balance at 1 July 2021 |
2,859 |
11,193 |
(721) |
282 |
10 |
(10,262) |
3,361 |
36 |
3,397 |
|
|
|
|
|
|
|
|
|
|
Loss for the period |
- |
- |
- |
- |
- |
(936) |
(936) |
(12) |
(948) |
Exchange difference on translation of foreign operations |
- |
- |
- |
(6) |
- |
- |
(6) |
- |
(6)
|
|
|
|
|
|
|
|
|
|
|
Total comprehensive income for the year |
- |
- |
- |
(6) |
- |
(936) |
(942) |
(12) |
(954) |
|
|
|
|
|
|
|
|
|
|
Issue of new shares |
57 |
201 |
- |
- |
- |
- |
258 |
- |
258 |
Issue costs related to equity |
- |
(14) |
- |
- |
- |
- |
(14) |
- |
(14) |
Share-based payment expense |
- |
- |
- |
- |
6 |
- |
6 |
- |
6 |
Increase holding in subsidiary |
- |
- |
- |
- |
- |
(493) |
(493) |
(24) |
(517) |
|
|
|
|
|
|
|
|
|
|
Balance at 31 December 2021 |
2,916 |
11,380 |
(721) |
276 |
16 |
(11,691) |
2,176 |
- |
2,176 |
|
|
|
|
|
|
|
|
|
|
Balance at 1 July 2020 |
1,738 |
8,288 |
(721) |
262 |
78 |
(7,941) |
1,704 |
28 |
1,732 |
|
|
|
|
|
|
|
|
|
|
Loss for the period |
- |
- |
- |
- |
- |
(1,378) |
(1,378) |
(36) |
(1,414) |
Exchange difference on translation of foreign operations |
- |
- |
- |
(16) |
- |
- |
(16) |
- |
(16)
|
|
|
|
|
|
|
|
|
|
|
Total comprehensive income for the year |
- |
- |
- |
(16) |
- |
(1,378) |
(1,394) |
(36) |
(1,430) |
|
|
|
|
|
|
|
|
|
|
Share-based payment expense |
- |
- |
- |
- |
(68) |
- |
(68) |
- |
(68) |
|
|
|
|
|
|
|
|
|
|
Balance at 31 December 2020 |
1,738 |
8,288 |
(721) |
246 |
10 |
(9,319) |
242 |
(8) |
234 |
|
|
|
|
|
|
|
|
|
|
Balance at 1 July 2020 |
1,738 |
8,288 |
(721) |
262 |
78 |
(7,941) |
1,704 |
28 |
1,732 |
|
|
|
|
|
|
|
|
|
|
Loss for the period |
- |
- |
- |
- |
- |
(2,266) |
(2,266) |
12 |
(2,254) |
Exchange difference on translation of foreign operations |
- |
- |
- |
20 |
- |
- |
20 |
- |
20 |
|
|
|
|
|
|
|
|
|
|
Total comprehensive income for the year |
|
|
- |
20 |
- |
(2,266) |
(2,246) |
12 |
(2,234) |
|
|
|
|
|
|
|
|
|
|
Issue of new shares |
1,121 |
3,379 |
- |
- |
- |
- |
4,500 |
- |
4,500 |
Issue costs deducted from equity |
- |
(474) |
- |
- |
- |
- |
(474) |
- |
(474) |
Share-based payment credit |
- |
- |
- |
- |
(68) |
- |
(68) |
- |
(68) |
Increase holding in subsidiary |
- |
- |
- |
- |
- |
(55) |
(55) |
(4) |
(59) |
|
|
|
|
|
|
|
|
|
|
Balance at 30 June 2021 |
2,859 |
11,193 |
(721) |
282 |
10 |
(10,262) |
3,361 |
36 |
3,397 |
1 See note 2.3 for a description of the prior year restatement.
Unaudited consolidated Statement of Cash Flows
For the six months ended 31 December 2021
|
|
£'000 |
Unaudited 6 months ended 31 December 2021 |
|
£'000 |
Unaudited 6 months ended 31 December 2020 (restated1) |
|
£'000 |
Audited year ended 30 June 2021
|
|
|
|
|
|
|
|
|
|
|
Net cash (used in)/inflow from operating activities |
|
|
(1,883) |
|
|
(934) |
|
|
(2,559) |
|
|
|
|
|
|
|
|
|
|
Investing activities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consideration paid for increased shareholding of subsidiary |
|
- |
|
|
- |
|
|
(59) |
|
Purchases of property, plant and equipment |
|
(4) |
|
|
(80) |
|
|
(114) |
|
Capitalisation of development costs |
|
(37) |
|
|
(71) |
|
|
(220) |
|
|
|
|
|
|
|
|
|
|
|
Net cash used in investing activities |
|
|
(41) |
|
|
(151) |
|
|
(393) |
|
|
|
|
|
|
|
|
|
|
Financing activities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net proceeds on issue of shares |
|
- |
|
|
- |
|
|
3,526 |
|
Proceeds from borrowings |
|
936 |
|
|
- |
|
|
500 |
|
Interest received / (paid) |
|
2 |
|
|
- |
|
|
(4) |
|
Cash divested on disposal of investment |
|
(12) |
|
|
- |
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
Net cash generated/(used) from financing activities |
|
|
926 |
|
|
- |
|
|
4,022 |
|
|
|
|
|
|
|
|
|
|
Net increase/(decrease) in cash and cash equivalents |
|
|
(998) |
|
|
(1,085) |
|
|
1,070 |
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at beginning of year |
|
|
2,338 |
|
|
1,241 |
|
|
1,241 |
|
|
|
|
|
|
|
|
|
|
Effect of foreign exchange rate changes |
|
|
(7) |
|
|
(5) |
|
|
27 |
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at end of year |
|
|
1,333 |
|
|
151 |
|
|
2,338 |
1 See note 2.3 for a description of the prior year restatement.
Notes to the consolidated financial statements
For the six months ended 31 December 2021
1. General information
InnovaDerma plc is a Group incorporated and domiciled in
The principal activity of the Group is the development, distribution and sale of skincare, haircare, beauty and life science products in the markets that it operates.
2. Accounting policies and critical accounting judgements
2.1 Basis of preparation
These financial statements are presented in pounds sterling because that is the currency of the primary economic environment in which the Group operates.
The Group's interim financial information has been prepared in accordance with IAS 34, 'Interim Financial Reporting as adopted by the EU.
The annual financial statements of the Group are prepared in accordance with the International Financial Reporting Standards ("IFRS") as adopted for use by the European Union. A copy of the statutory accounts for the year ended 30 June 2021 has been delivered to the Registrar of Companies. The auditor's report on those accounts was unqualified and did not contain any statements under Section 498(2) or (3) of the Companies Act 2006.
The same accounting policies, presentation and methods of computation have been followed in this unaudited interim financial information as those which were applied in the preparation of the Group's annual financial statements for the year ended 30 June 2021.
Certain new standards, amendments to standards and interpretations are not year effective for the year ended 30 June 2022 and have therefore not been applied in preparing this interim financial information.
The interim accounts are unaudited and do not constitute statutory accounts as defined in Section 434 of the Companies Act 2006.
2.2 Going concern
The Directors have, at the time of approving the financial statements, a reasonable expectation that the Company and the Group have adequate resources to continue in operational existence for the foreseeable future. In reaching this conclusion the Directors have considered the financial position of the Group, its cash, liquidity position and borrowing facilities together with its forecasts and projections for 12 months from the approval date that take into account reasonably possible changes in trading performance. The going concern basis of accounting has therefore continued to be adopted in preparing the financial statements.
The Group has taken into account the uncertainty due to the economic impact of COVID-19, and has made prudent forecasts, incorporating mitigating actions, based on current knowledge. It has also secured a CBILS loan of
2.3 Prior year restatement
The Group has restated the prior year comparatives to correct the following prior period accounting errors:
· To expense marketing costs incorrectly capitalised totalling
· Write down inventory due to incorrect allocation of cost of sales by
· Reclassify Prolong intellectual property of
· Impairment of goodwill on acquisitions of
· An amortisation charge relating to intangible assets, totalling
·
· Register accruals totalling
· Recognise
· Recognise expense totalling
· Register
· Recognise
·
· Recognise amortisation of
· Recognise corporation tax charges for the year ended 30 June 2017 of
· Derecognise a deferred tax asset of
· To reclassify exceptional items of
· Reduce corporation tax liability by
· Reduce the non-controlling interest by
These changes have had a material impact on the Group's reported statement of comprehensive income and statement of financial position for the financial year 31 December 2020. Please refer to note 11 for further details of the restatement.
3. Operating segments
The Group derives revenue from the sale of skin and beauty, haircare and life science products. The income streams are all derived from the utilisation of these products which, in all aspects except details are revenue, are reviewed and managed together within the Group and as such are considered to be only one segment.
A geographical analysis of the revenue from the Group's customers, by destination, is as follows:
|
|
Unaudited 6 months ended 31 December 2021 £'000 |
|
Unaudited 6 months ended 31 December 2020 (restated) £'000 |
|
Audited year ended 30 June 2021 £'000 |
|
|
|
|
|
|
|
|
|
2,754 |
|
2,833 |
|
7,919 |
|
|
309 |
|
360 |
|
1,151 |
|
|
626 |
|
884 |
|
1,141 |
|
|
|
|
|
|
|
|
|
3,689 |
|
4,077 |
|
10,211 |
4. Revenue
The Group's revenues from products and services were as follows:
|
|
Unaudited 6 months ended 31 December 2021 £'000 |
|
Unaudited 6 months ended 31 December 2020 (restated) £'000 |
|
Audited year ended 30 June 2021 £'000 |
|
|
|
|
|
|
|
Skin and beauty products |
|
3,462 |
|
3,780 |
|
9,610 |
Haircare products |
|
173 |
|
243 |
|
440 |
Life science devices |
|
54 |
|
54 |
|
161 |
|
|
|
|
|
|
|
|
|
3,689 |
|
4,077 |
|
10,211 |
5. Loss from operations
Loss before tax for the year has been arrived at after (crediting)/charging:
|
|
Unaudited 6 months ended 31 December 2021 £'000 |
|
Unaudited 6 months ended 31 December 2020 (restated) £'000 |
|
Audited year ended 30 June 2021 £'000 |
|
|
|
|
|
|
|
Depreciation |
|
43 |
|
17 |
|
35 |
Amortisation |
|
50 |
|
58 |
|
116 |
Net foreign exchange losses/(gains) |
|
(1) |
|
(8) |
|
140 |
Cost of inventories recognised as an expense |
|
1,112 |
|
1,386 |
|
2,918 |
Non-recurring items including impairments, abortive and restructuring |
35 |
|
196 |
|
210 |
|
Share-based payment expense |
|
6 |
|
(68) |
|
(68) |
Directors' remuneration |
|
224 |
|
155 |
|
438 |
Staff costs |
|
807 |
|
905 |
|
1,731 |
Adjusted EBITDA
Adjusted EBITDA has been arrived at after accounting for:
|
|
Unaudited 6 months ended 31 December 2021 £'000 |
|
Unaudited 6 months ended 31 December 2020 (restated) £'000 |
|
Audited year ended 30 June 2021 £'000 |
|
|
|
|
|
|
|
Operating loss before tax |
|
(950) |
|
(1,414) |
|
(1,883) |
|
|
|
|
|
|
|
Depreciation |
|
43 |
|
17 |
|
35 |
Amortisation |
|
50 |
|
58 |
|
116 |
Loss on disposal of investment |
|
138 |
|
- |
|
- |
Foreign exchange losses/(gains) on intercompany loans |
(16) |
|
21 |
|
135 |
|
Non-recurring items including impairments, abortive and restructuring |
35 |
|
196 |
|
210 |
|
Share-based payment (credit)/expense |
|
6 |
|
(68) |
|
(68) |
|
|
|
|
|
|
|
Adjusted EBITDA |
|
(694) |
|
(1,190) |
|
(1,455) |
6. Taxation
Analysis of tax (charge) / credit for the period:
|
|
Unaudited 6 months ended 31 December 2021 £'000 |
|
Unaudited 6 months ended 31 December 2020 (restated) £'000 |
|
Audited year ended 30 June 2021 £'000 |
|
|
|
|
|
|
|
Current tax |
|
- |
|
- |
|
(1) |
Deferred tax |
|
- |
|
(2) |
|
(370) |
|
|
|
|
|
|
|
|
|
- |
|
(2) |
|
(371) |
7. Losses per share
|
|
Unaudited 6 months ended 31 December 2021 |
|
Unaudited 6 months ended 31 December 2020 (restated) |
|
Audited year ended 30 June 2021 |
Losses for the purposes of basic and diluted losses per share being net losses attributable to owners of the Group |
|
942 |
|
1,394 |
|
2,246 |
|
|
|
|
|
|
|
|
|
2021 |
|
2020 |
|
2020 |
Number of shares |
|
Number |
|
Number |
|
Number |
Weighted average number of ordinary shares for the purposes of basic and diluted losses per share |
|
27,378,386 |
|
14,496,633 |
|
17,449,621 |
Loss per share
|
|
Unaudited 6 months ended 31 December 2021 £ |
|
Unaudited 6 months ended 31 December 2020 (restated) £ |
Audited year ended 30 June 2021 £
|
Basic and diluted |
|
(0.03) |
|
(0.10) |
(0.13) |
IAS 33 requires presentation of diluted EPS when a Group could be called upon to issue shares that would decrease earnings per share or increase the loss per share. For a loss-making Group with outstanding share options, the net loss per share would be decreased by the exercise of options. Therefore, as per IAS33:36, the anti-dilutive potential ordinary shares are disregarded in the calculation of diluted EPS.
8. Notes to the cash flow statement
|
|
Unaudited 6 months ended 31 December 2021 £'000 |
|
Unaudited 6 months ended 31 December 2020 (restated) |
|
Audited year ended 30 June 2021 £'000 |
|
|
|
|
|
|
|
Operating loss before tax |
|
(950) |
|
(1,414) |
|
(1,883) |
|
|
|
|
|
|
|
Adjustments for: |
|
|
|
|
|
|
Finance costs |
|
(2) |
|
- |
|
4 |
Depreciation |
|
43 |
|
17 |
|
35 |
Amortisation |
|
50 |
|
58 |
|
116 |
Loss on disposal of investment |
|
138 |
|
- |
|
- |
Share-based payment expense |
|
6 |
|
(68) |
|
(68) |
|
|
|
|
|
|
|
Operating cash flows before movements in working capital |
|
(715) |
|
(1,407) |
|
(1,796) |
|
|
|
|
|
|
|
Decrease / (increase) in inventories |
|
(515) |
|
(1,136) |
|
(533) |
Decrease / (increase) in receivables |
|
527 |
|
599 |
|
(306) |
(Decrease) / increase in payables |
|
(1,080) |
|
1,010 |
|
77 |
|
|
|
|
|
|
|
Cash used in operations |
|
(1,783) |
|
(934) |
|
(2,558) |
|
|
|
|
|
|
|
Income taxes received / (paid) |
|
(100) |
|
- |
|
(1) |
|
|
|
|
|
|
|
Net cash used in operating activities |
|
(1,883) |
|
(934) |
|
(2,559) |
9. Related party transactions
On 3 December 2021, Ergon Medical Limited, a wholly owned subsidiary of InnovaDerma plc, subdivided its 3,614
On 3 December 2021, InnovaDerma plc signed a deed of release forgiving in full debt totalling
Other than those disclosed within this note, there have been no other transactions with related parties.
10. Events after the reporting date
The Directors confirm that there are no events after the reporting date which require disclosure.
11. Prior period restatement
The comparative figures for the six months ended 31 December 2020 have been restated to correct the prior period accounting errors disclosed in note 2.3. The following tables show the financial impact of the restatements by comparing the previously stated and the now restated Statement of Comprehensive Income and Statement of Financial Position.
|
As reported 6 months ended 31 December 2020 £'000 |
Restatements 2020 £'000 |
As restated 6 months ended 31 December 2020 £'000 |
|
|
|
|
Continuing operations |
|
|
|
Revenue |
4,145 |
(68) |
4,077 |
Cost of sales |
(2,078) |
14 |
(2,064) |
|
|
|
|
Gross profit |
2,067 |
(54) |
2,013 |
|
|
|
|
Other operating income |
59 |
(59) |
- |
Listing expenses |
(76) |
76 |
- |
Marketing expenses |
(1,626) |
(6) |
(1,632) |
Wages & salaries expenses |
(906) |
69 |
(837) |
Administrative expenses |
(544) |
(414) |
(958) |
Exceptional items |
(196) |
196 |
- |
|
|
|
|
Operating loss |
(1,222) |
(192) |
(1,414) |
|
|
|
|
Finance cost |
- |
- |
- |
|
|
|
|
Operating loss before tax |
(1,222) |
(192) |
(1,414) |
|
|
|
|
Income Tax expense |
173 |
(173) |
- |
|
|
|
|
Net loss for the period |
(1,049) |
(365) |
(1,414) |
|
|
|
|
Other comprehensive Income |
6 |
(6) |
- |
|
|
|
|
Exchange loss on foreign currency net investments |
- |
(16) |
(16) |
|
|
|
|
Total comprehensive income for the period |
(1,043) |
(387) |
(1,430) |
|
|
|
|
Attributable to: |
|
|
|
Owners of the parent |
(1,020) |
(374) |
(1,394) |
Non-controlling interests |
(23) |
(13) |
(36) |
|
|
|
|
Loss per share |
|
|
|
- basic and diluted (£) |
(0.07) |
(0.03) |
(0.10) |
|
|
|
|
|
£'000 |
As reported as at 31 December 2020 £'000 |
|
£'000 |
Restatements 2020 £'000 |
|
£'000 |
As restated as at 31 December 2020 £'000 |
Non-current assets |
|
|
|
|
|
|
|
|
Intangible assets |
|
8,003 |
|
|
(8,003) |
|
|
- |
Goodwill |
|
- |
|
|
439 |
|
|
439 |
Other intangible assets |
|
- |
|
|
115 |
|
|
115 |
Property, plant and equipment |
|
157 |
|
|
68 |
|
|
225 |
Deferred tax asset |
|
400 |
|
|
(18) |
|
|
382 |
Other assets |
|
16 |
|
|
(16) |
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
8,576 |
|
|
(7,415) |
|
|
1,161 |
|
|
|
|
|
|
|
|
|
Current assets |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
156 |
|
|
(5) |
|
|
151 |
|
Inventories |
4,142 |
|
|
(1,731) |
|
|
2,411 |
|
Trade and other receivables |
725 |
|
|
266 |
|
|
991 |
|
Prepayments and other assets |
500 |
|
|
(500) |
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
5,523 |
|
|
(1,970) |
|
|
3,553 |
|
|
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
|
Trade and other payables |
(4,745) |
|
|
265 |
|
|
(4,480) |
|
|
|
|
|
|
|
|
|
|
Net current assets |
|
778 |
|
|
(1,705) |
|
|
(927) |
|
|
|
|
|
|
|
|
|
Total assets less current liabilities |
|
9,354 |
|
|
(9,120) |
|
|
234 |
|
|
|
|
|
|
|
|
|
Non-current liabilities |
|
|
|
|
|
|
|
|
Borrowings |
|
(1) |
|
|
1 |
|
|
- |
|
|
|
|
|
|
|
|
|
Net assets |
|
9,353 |
|
|
(9,119) |
|
|
234 |
|
|
|
|
|
|
|
|
|
Equity |
|
|
|
|
|
|
|
|
Share capital |
|
1,736 |
|
|
2 |
|
|
1,738 |
Share premium account |
|
8,288 |
|
|
- |
|
|
8,288 |
Merger reserve |
|
(721) |
|
|
- |
|
|
(721) |
Foreign exchange reserve |
|
(162) |
|
|
408 |
|
|
246 |
Share-based payment reserve |
|
- |
|
|
10 |
|
|
10 |
Accumulated profit/(loss) |
|
36 |
|
|
(9,355) |
|
|
(9,319) |
|
|
|
|
|
|
|
|
|
Equity attributable to owners of parent |
|
9,177 |
|
|
(8,935) |
|
|
242 |
|
|
|
|
|
|
|
|
|
Non-controlling interest |
|
176 |
|
|
(184) |
|
|
(8) |
|
|
|
|
|
|
|
|
|
Total equity |
|
9,353 |
|
|
(9,119) |
|
|
234 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.